FibroGen wins orphan designation for IPF drug

FibroGen Inc.'s mid-stage experimental treatment for the lung-scarring disease idiopathic pulmonary fibrosis was granted orphan drug designation. The drug, FG-3019, is a human monoclonal antibody designed to inhibit connective tissue growth factor, a protein that plays an important role in the build up of excessive fibrous tissue in diseases like IPF.